Hodgkin Lymphoma News and Research

RSS
Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

SCT transplantation benefits in Hodgkin's lymphoma is unclear

SCT transplantation benefits in Hodgkin's lymphoma is unclear

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

U.S. House of Representatives declares September 2010 as 'Blood Cancer Awareness Month'

U.S. House of Representatives declares September 2010 as 'Blood Cancer Awareness Month'

National survey highlights need for greater awareness on lymphoma

National survey highlights need for greater awareness on lymphoma

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

CSC launches new educational program to enhance lymphoma patient, physician communication

CSC launches new educational program to enhance lymphoma patient, physician communication

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Stand Up To Cancer prepares for next Team Fundraising Challenge

Stand Up To Cancer prepares for next Team Fundraising Challenge

CTI announces EMEA's validation of expanded PIP for pixantrone

CTI announces EMEA's validation of expanded PIP for pixantrone

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Micromet second-quarter 2010 total revenues increase to $6.5 million

Micromet second-quarter 2010 total revenues increase to $6.5 million

CTI second-quarter total net operating expenses decrease to $20.0 million

CTI second-quarter total net operating expenses decrease to $20.0 million

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL

CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.